Ayala Pharma, an Israeli oncology company built around targeted cancer therapies licensed from Bristol-Myers Squibb Co., has raised $17m to take its lead asset into Phase II trials.
The emerging company, based in Rehovot, was founded in December 2017 and is backed by local investors Israeli Biotech Fund...
Welcome to Scrip
Create an account to read this article
Already a subscriber?